Clayton, one of the largest home builders in America, helped fulfill the dreams of an East Tennessee Children’s Hospital cancer patient by giving him the opportunity to design a Clayton home using CAD software commonly used at home building facilities.
Jake Clark, 16, became an honorary member of the Clayton team on Nov. 22 during a special ‘Team Jake’ celebration event at a home building facility in Bean Station, Tenn. His interests in construction projects with his dad, a home contractor, and his talents in drawing and 3D design made Jake the perfect fit to visit Clayton. While visiting the home building facility, the cancer survivor sat with a home designer and created a home model floor plan of his own, which was named “The Jake” in his honor.
To view the multimedia release go to:
https://www.multivu.com/players/English/80116510-clayton-honors-young-cancer-survivor/
Featuring a noted cancer researcher, animal behaviorists and a 14-year-old entrepreneur who developed a new product to ease pets’ separation anxiety, Purina’s second Better With Pets Summit emphasized how technology and scientific advances are leading to a brighter future with our pets. The daylong event, Tuesday, in New York City featured 15 expert presentations on scientific, nutritional and behavioral innovations to help better understand why our lives are better with pets.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7325551-purina-better-with-pets-summit-2014/
Invuity, Inc. (NASDAQ:IVTY), an advanced medical technology company, announced today the launch of its Hidden ScarTM Surgery program designed to certify surgeons and establish Centers of Excellence at major cancer centers and hospitals across the country. This innovative program will train surgeons on advanced minimally invasive and minimal access surgical approaches that deliver optimal clinical and aesthetic outcomes for patients. As part of the company’s broader women’s health initiative, Invuity is hosting a Hidden Scar Breast Cancer Surgery training course in advance of the American College of Surgeons (ACS) Clinical Congress.
Invuity aims to transform the surgical treatment of breast cancer with this advanced surgical approach for nipple sparing mastectomies and lumpectomies (breast conserving surgery). Hidden Scar Breast Cancer Surgery expands surgical options for patients, offering superior cosmetic outcomes that can improve their psychological and emotional recovery and enhance quality of life after surgery.1
With growing demand for less invasive alternatives to breast cancer surgery, surgeons need to operate through smaller incisions with limited fields of vision. Invuity’s illumination technology allows surgeons to access and visualize the entire breast cavity through discrete incision locations, enabling surgeons to safely and effectively treat breast cancer while preserving the natural shape of the breast and thereby minimizing and hiding the scars.
To view the multimedia release go to:
http://www.multivu.com/players/English/7644051-invuity-hidden-scar-breast-cancer-surgery-program/
Dr. Julia Capua, a brilliant neurosurgeon, faces the prospect of raising their son alone when her
husband, Dr. Roman Montague, the famous neuroscientist is diagnosed with terminal cancer.
Will she make the impossible choice to save the one she loves, and can she live with the consequences?
The Immortal: How Far Would You Go to Save the One You Love?
Find out more at http://www.the-immortal.com Scifi/Thriller
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
The Prostate Cancer Foundation is throwing a one-two punch to knock out prostate cancer for good with the recent production of a public service announcement featuring boxing legend and five-time heavyweight champion of the world Evander Holyfield. The message encourages African-American men to get regularly checked for prostate cancer because they are more than twice as likely to develop this disease than any other type of cancer.
To view the Multimedia News Release, go http://www.multivu.com/players/English/7545851-pcf-holyfield-prostate-cancer-psa/
Let’s Win, an initiative supported by the Lustgarten Foundation, launched the Let’s Win! Pancreatic Cancer Survivors video series Friday, January 19, 2018, at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The new online video series, featuring long-term pancreatic cancer survivors of all ages and diverse backgrounds, has been created to show pancreatic cancer patients and their families that people do survive this disease. The survivors have responded exceptionally well to pancreatic cancer therapy that incorporates clinical trials and treatments that go beyond traditional protocols.
When patients are first diagnosed with pancreatic cancer, they often turn to the internet, only to find devastating and frightening statistics about the disease. “Our goal is to provide hope and inspiration to patients and their families,” says Cindy Gavin, founding executive director of Let’s Win. “We are so grateful for the incredible vision of one special patient and the generosity of The Flora Family Foundation for their support of this incredible initiative.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213752-lets-win-pancreatic-cancer-survivor-video-series/
The sixth annual Productive Innovation Index released by IDEA Pharma today, which ranks biopharmaceutical companies by their ability to successfully bring innovations to market, sees Johnson & Johnson top the industry for the fourth year running.
The Productive Innovation Index measures, scores and celebrates a company’s ability to deliver innovation to patients, by objectively evaluating performance data based on a rolling five year period (2010-2015), and operates on the premise: if you gave the same molecule to two different companies in early phase, which would make the best of it?
The success of the Janssen Pharmaceutical Companies of Johnson & Johnson and its consolidation of 1st place across the past four years’ rankings is driven largely by innovations in the field of oncology, immunology, neuroscience and cardiovascular/metabolism. Notable performers include Zytiga® (prostate cancer), Imbruvica® (chronic lymphocytic leukemia and mantle cell lymphoma (co-developed and co-marketed with Pharmacyclics, an AbbVie company)), Simponi®/Simponi Aria® (rheumatoid arthritis), Stelara® (psoriasis and psoriatic arthritis), Invega Sustenna® and Invega Trinza® (schizophrenia).
To view the multimedia release go to:
http://www.multivu.com/players/uk/7770851-johnson-and-johnson-tops-idea-pharma/
Imagine being diagnosed with one of the most rare and aggressive forms of breast cancer, given a five percent chance to live and told having children will never be an option. Southern California local Kommah McDowell was told just that— and then she went to City of Hope.
It is estimated that almost 40 percent of men and women in the U.S. will be diagnosed with cancer sometime during their lifetime. Kommah, who was diagnosed at age 29, now has her health and her son, thanks to discoveries made at City of Hope, where scientists and doctors turn laboratory breakthroughs into treatments that defeat cancer.
Today, the nonprofit research and comprehensive cancer center near Los Angeles is rolling out a new initiative that builds on its legacy of discovery to let people know that City of Hope not only offers a uniquely patient-centric, integrated approach to care, but also with the help of donors and volunteers, it is pursuing research that will change the future of medicine.
To view the multimedia release go to:
http://www.multivu.com/players/English/7665051-city-of-hope-miracle-science-soul-campaign/
CVS Health, the nation’s largest pharmacy innovation company, today launched an in-store fundraising campaign at CVS Pharmacy locations nationwide to benefit the American Lung Association’s LUNG FORCE initiative which aims to make lung cancer, the leading cancer killer of women in the United States, a public health priority.
Now through June 11, customers can donate $1, $3 or more at the register at 7,900 CVS Pharmacy locations and online at www.cvs.com/lung (all proceeds will support the initiative). CVS Health is the national presenting sponsor of LUNG FORCE, which is focused on raising awareness about lung cancer in women, and increasing research funding to save lives.
To view the multimedia release go to:
http://www.multivu.com/players/English/7817251-cvs-health-lung-force-fundraiser/
With September marking National Prostate Cancer Awareness Month and the kick-off of the 2015 NFL season, the Urology Care Foundation and the NFL have renewed their commitment to driving prostate health awareness, as well as teamed up to highlight a Public Service Announcement (PSA) focused on educating men about prostate cancer and encouraging them to take charge of their health through the Know Your Stats® campaign.
The Know Your Stats® campaign is a rallying force to connect, educate and inspire men across the country to know their prostate cancer risk and talk to their doctor about whether prostate cancer testing is right for them.
“It is important for men to know their risk and talk to their doctors so they can determine if prostate cancer testing is right for them,” said Richard A. Memo, MD, Chair of the Urology Care Foundation. “Having the tools and facts empowers individuals and their doctors to make informed decisions.”
Prostate cancer is the second most common cancer in America, affecting one in seven men. Odds increase to one in five if they are African American and one in three if they have a family history; however, the educational tools are making an impact. More men are talking with their doctors and getting tested, and fewer men are dying from the disease.
To view the multimedia release go to:
http://www.multivu.com/players/English/7365551-prostate-cancer-know-your-stats-psa/
Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. The test utilizes combined assays for genetic alterations and protein biomarkers and has the capacity not only to identify the presence of relatively early cancer, but also to localize the organ of origin of these cancers.
“The potential this has for pancreatic cancer is unprecedented,” says Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine, Director, Pancreatic Cyst Center of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. “We know that in 80-85 percent of pancreatic cancer cases, it’s detected too late, leaving the patient with few options. Developing a blood screening test for pancreatic cancer has been an urgent goal, because catching the disease early will be the way we get to long-term survival.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213751-lustgarten-foundation-pancreatic-cancer-blood-test/
